Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 20, 2024
Discovery & Translation
Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 3, 2019
Targets & Mechanisms
ALS platform trial to put neuroinflammation hypothesis to the test
The idea that neuroinflammation drives ALS will get its most rigorous test to date with the Healey ALS platform trial.
BioCentury | Feb 22, 2019
Emerging Company Profile
Gyroscope complements dry AMD
Gyroscope's one-shot dry AMD therapy supplies an upstream complement factor
BioCentury | Jul 11, 2017
Emerging Company Profile
Complementary ALS play
Why Alsonex is targeting the complement system at C5a to treat ALS
BioCentury | May 26, 2016
Product R&D
H is for cancer
How an antibody from NSCLC patients uses complement to kill cancer
BioCentury | Jan 21, 2016
Distillery Therapeutics
Therapeutics: CD59; complement C5b-9 membrane attack complex (MAC)
Items per page:
1 - 10 of 26